CN1281210C - 五味子乙素在制备治疗肿瘤药物中的应用 - Google Patents
五味子乙素在制备治疗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN1281210C CN1281210C CNB2004100596073A CN200410059607A CN1281210C CN 1281210 C CN1281210 C CN 1281210C CN B2004100596073 A CNB2004100596073 A CN B2004100596073A CN 200410059607 A CN200410059607 A CN 200410059607A CN 1281210 C CN1281210 C CN 1281210C
- Authority
- CN
- China
- Prior art keywords
- cell
- schisandrin
- tumor
- group
- adr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Drug | Ctrl | SchB | RF | Ver | RF |
紫杉醇阿霉素米托蒽醌柔红霉素长春新碱表阿霉素高三尖杉酯羟基喜树碱 | 0.3423±0.13221.4175±0.24630.1052±0.03560.5046±0.07280.9162±0.2381.3196±0.32180.4283±0.10790.3688±0.0875 | 0.01913±0.02080.1691±0.0137<0.010.0977±0.0630.1486±0.05540.3033±0.08120.0964±0.03120.0417±0.062 | 17.898.38>10.525.166.174.354.448.84 | 0.0143±0.00930.1324±0.0086<0.010.0791±0.03130.0872±0.02360.2218±0.09090.0701±0.00420.0432±0.0205 | 23.9410.76>10.526.3810.515.956.038.53 |
Drug | Ctrl | Schb | RF | Ver | RF |
阿霉素米托蒽醌柔红霉素长春新碱表阿霉素高三尖杉酯羟基喜树碱紫杉醇 | 0.3272±0.21310.0906±0.04560.3046±0.0728>200.9876±0.15240.5257±0.19870.1618±0.15010.0890±0.0079 | 0.0691±0.0137<0.010.0913±0.0030.1572±0.09460.1033±0.05450.1064±0.08120.0527±0.06130.0316±0.0019 | 4.74>9.063.34127.39.564.943.072.85 | 0.0324±0.0086<0.010.0555±0.01750.9872±0.01550.1226±0.08250.1108±0.00760.0468±0.02540.0329±0.0079 | 10.11>9.065.4920.268.054.743.482.70 |
(%apoptosis) | |||||
Cell | Ctrl | A1 | A5 | A1+S10 | A5+S10 |
KBV200KB | 1.2%0.8% | 1.7%>90% | 7.6% | 46.1%>90% | >90% |
Treatment(μg/ml) | Cell cycle distribution(%) | Apoptosis(%) | ||
G0/G1 | S | G2/M | ||
A1 | 44.76 | 45.09 | 10.14 | 1.21 |
A5 | 48.03 | 42.37 | 9.60 | 7.51 |
A1+S10 | 54.04 | 40.30 | 5.66 | 24.10a |
A5+S10 | 58.94 | 39.36 | 1.70 | 70.31b |
药物处理 | 细胞凋亡(%) | 药物处理 | 细胞凋亡(%) |
A0.1 | 9.6 | S10+A0.1 | 8.2c |
A1 | 67.1 | S10+A1 | 72.3d |
组 | 动物数 | 存活时间(天) | 生命延长率T/C(%) |
NS | 7 | 20.8 | 100 |
PT | 7 | 19.9 | 95.7 |
SchB | 7 | 21.2 | 101.4 |
ADR | 8 | 23.1 | 111.7 |
ASB | 10 | 27.9 | 134.5* |
Claims (9)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100596073A CN1281210C (zh) | 2003-11-29 | 2004-06-11 | 五味子乙素在制备治疗肿瘤药物中的应用 |
US10/998,025 US20050119337A1 (en) | 2003-11-28 | 2004-11-24 | Methods of application of Schisandrin B in the preparation of anticancer medications |
PCT/CN2004/001360 WO2005051377A1 (fr) | 2003-11-29 | 2004-11-26 | Utilisation de la schisandrine b dans la fabrication de medicaments utilises dans le traitement des maladies tumorales |
US11/173,567 US20050282910A1 (en) | 2003-11-28 | 2005-07-01 | Methods of application of chemical compounds having therapeutic activities in treating cancers |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200310108996 | 2003-11-29 | ||
CN200310108996.X | 2003-11-29 | ||
CNB2004100596073A CN1281210C (zh) | 2003-11-29 | 2004-06-11 | 五味子乙素在制备治疗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1621037A CN1621037A (zh) | 2005-06-01 |
CN1281210C true CN1281210C (zh) | 2006-10-25 |
Family
ID=34621067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100596073A Expired - Fee Related CN1281210C (zh) | 2003-11-28 | 2004-06-11 | 五味子乙素在制备治疗肿瘤药物中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20050119337A1 (zh) |
CN (1) | CN1281210C (zh) |
WO (1) | WO2005051377A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050282910A1 (en) * | 2003-11-28 | 2005-12-22 | Xun Hu | Methods of application of chemical compounds having therapeutic activities in treating cancers |
US7276257B2 (en) * | 2005-07-22 | 2007-10-02 | The Hong Kong University Of Science And Technology | Schisandrin B preparation |
CN1994289B (zh) * | 2006-01-05 | 2010-06-09 | 胡汛 | 联苯环辛二烯木脂素在制备酪氨酸激酶抑制药物中的应用 |
CN103156828B (zh) * | 2011-12-13 | 2016-10-12 | 天津市国际生物医药联合研究院 | 联苯环辛烯型木脂素在抗sars冠状病毒感染中的应用 |
CN104147001A (zh) * | 2013-05-15 | 2014-11-19 | 浙江大学 | 五味子乙素在制备nadph氧化酶抑制剂中的应用 |
CN105079096A (zh) * | 2015-09-07 | 2015-11-25 | 吉林大学 | 一种胃癌术后辅助治疗减毒增效的中药组合物 |
CN112457384B (zh) * | 2020-12-17 | 2023-03-28 | 浙江天美供应链管理有限公司 | 一种酶解多肽及用于制备抗白血病的药物的用途 |
CN112675164A (zh) * | 2021-01-14 | 2021-04-20 | 大连大学 | 五味子乙素抑制鼻咽癌细胞药物型制剂的应用 |
CN113604420B (zh) * | 2021-07-07 | 2022-07-08 | 南方医科大学珠江医院 | 体外诱导人胎盘间充质干细胞分化为肝细胞的方法及含五味子乙素的组合物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US593954A (en) * | 1897-11-16 | Chest and neck protector | ||
CA1334752C (en) * | 1988-08-02 | 1995-03-14 | Ryozo Sakoda | Drug effect-enhancing agent for antitumor drug |
US6911454B1 (en) * | 1989-09-28 | 2005-06-28 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant disease |
US5005588A (en) * | 1989-10-13 | 1991-04-09 | David Rubin | Method for increasing tumor sensitivity to chemotherapy |
US5681812A (en) * | 1991-12-10 | 1997-10-28 | Rush Presbyterian-St. Luke's Medical Center | Methods and compositions for reducing multidrug resistance |
US6171786B1 (en) * | 1992-09-17 | 2001-01-09 | Board Of Trustees Of University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
US5543428A (en) * | 1994-08-31 | 1996-08-06 | Eli Lilly And Company | Method for treating resistant tumors |
IL115582A0 (en) * | 1994-10-14 | 1996-01-19 | Lilly Co Eli | Methods for treating resistant tumors |
US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
US6011069A (en) * | 1995-12-26 | 2000-01-04 | Nisshin Flour Milling Co., Ltd. | Multidrug resistance inhibitors |
US5717092A (en) * | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
EP0814081A1 (en) * | 1996-06-17 | 1997-12-29 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
US5869650A (en) * | 1996-06-21 | 1999-02-09 | Fox Chase Cancer Center | Dendroamide compounds and their use in chemosensitizing multidrug resistant cells |
EA200001035A1 (ru) * | 1998-04-08 | 2001-04-23 | Эли Лилли Энд Компани | Способ ингибирования mrp1 |
JP2002510624A (ja) * | 1998-04-08 | 2002-04-09 | イーライ・リリー・アンド・カンパニー | Mrp1の阻害方法 |
US6372775B1 (en) * | 1998-05-27 | 2002-04-16 | American Cyanamid Company | Reversal of multidrug resistance in human colon carcinoma cells |
AU7824900A (en) * | 1999-10-07 | 2001-04-23 | Eli Lilly And Company | Compounds and methods for inhibiting mrp1 |
CN1112183C (zh) * | 1999-12-01 | 2003-06-25 | 潘思源 | 五味子素的新用途 |
US6743794B2 (en) * | 1999-12-22 | 2004-06-01 | Eli Lilly And Company | Methods and compounds for inhibiting MRP1 |
CA2413579A1 (en) * | 2000-06-23 | 2002-01-03 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
US6703400B2 (en) * | 2001-02-23 | 2004-03-09 | Schering Corporation | Methods for treating multidrug resistance |
US6605305B2 (en) * | 2001-04-04 | 2003-08-12 | Xinxian Zhao | Plant drug for treatment of liver disease |
US6630454B2 (en) * | 2001-09-10 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Method and pharmaceutical composition for the treatment of cancer |
CN1208080C (zh) * | 2003-04-08 | 2005-06-29 | 黑龙江省医药工业研究所 | 五仁醇胶囊作为制备治疗失眠药物的应用 |
-
2004
- 2004-06-11 CN CNB2004100596073A patent/CN1281210C/zh not_active Expired - Fee Related
- 2004-11-24 US US10/998,025 patent/US20050119337A1/en not_active Abandoned
- 2004-11-26 WO PCT/CN2004/001360 patent/WO2005051377A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20050119337A1 (en) | 2005-06-02 |
CN1621037A (zh) | 2005-06-01 |
WO2005051377A1 (fr) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | Synthesis and antiviral activity of coumarin derivatives against infectious hematopoietic necrosis virus | |
CN1281210C (zh) | 五味子乙素在制备治疗肿瘤药物中的应用 | |
Jiang et al. | Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB/c mice | |
CN106029070A (zh) | 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途 | |
CN102526022A (zh) | 表没食子儿茶素没食子酸酯在制备抗肿瘤药物中的应用 | |
Jayameena et al. | Rutin: A potential anticancer drug against human colon cancer (HCT116) cells | |
Zhao et al. | Shenxian-Shengmai oral liquid reduces myocardial oxidative stress and protects myocardium from ischemia-reperfusion injury | |
Rajkumar et al. | Isolation and bioactivity evaluation of two metabolites from the methanolic extract of Oroxylum indicum stem bark | |
Li et al. | Sanguinarine induces apoptosis in eimeria tenella sporozoites via the generation of reactive oxygen species | |
CN112353797B (zh) | 吲哚-3-乙腈在制备治疗或预防流感病毒感染的药物中的应用 | |
CN1868468A (zh) | 毛萼乙素在制药中的应用 | |
US20090247495A1 (en) | Cucurbitacin b and uses thereof | |
KR20120020639A (ko) | 단삼을 포함하는 전립선암 치료용 조성물 | |
CN1425667A (zh) | 一种具有抗肿瘤作用的新化合物、其制备方法及在制备治疗肿瘤药物中的应用 | |
CN106999596A (zh) | 菜蓟滴定提取物及其用途 | |
Li et al. | Anticancer activity of mukonal against human laryngeal cancer cells involves apoptosis, cell cycle arrest, and inhibition of PI3K/AKT and MEK/ERK signalling pathways | |
CN1283238C (zh) | 紫草素在制备治疗肿瘤疾病药物中的用途 | |
CN111789830B (zh) | 2-(2,2,2-三氟亚乙基)-1,3-二酮化合物在制备抗肺癌的药物中的应用 | |
CN108403690A (zh) | 一种抑制黑色素瘤细胞增殖的药物及其应用 | |
Feng et al. | Compound C17 inhibits the lung metastasis of breast cancer. | |
Qayyum et al. | Design, synthesis and preclinical evaluations of (s)-2-((s)-1-benzyl-2, 5-dioxopyrrolidin-3-yl)-3-(4-isopropylphenyl)-2-methylpropanal (succ-5) as cardioprotective, hepatoprotective and lipid lowering molecule. in-vivo and in-silico approaches | |
CN109602739A (zh) | 青蒿琥酯在制备抑制肿瘤细胞耐药性药物中的应用 | |
CN104000835B (zh) | P糖蛋白抑制剂 | |
CN111481534A (zh) | 3,4断裂的环阿尔廷型三萜类化合物在制备自噬抑制剂及抗肿瘤药物中的应用 | |
Hao et al. | In vitro study of the nephrotoxicity of tripterygium tablet extract and triptolide in monolayer HK-2 cells cultured in a transwell chamber |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: NINGBO INNO PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110322 Address after: Hangzhou City, Zhejiang province 310009 City District primary and generous Donghe homes 1-2-503 Patentee after: Hu Xun Address before: Hangzhou City, Zhejiang province 310009 City District primary and generous Donghe homes 1-2-503 Co-patentee before: Ningbo Yingnuo Pharmaceutical Technology Co., Ltd. Patentee before: Hu Xun |
|
ASS | Succession or assignment of patent right |
Owner name: GAO CHENYONG Free format text: FORMER OWNER: HU XUN Effective date: 20120409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310009 HANGZHOU, ZHEJIANG PROVINCE TO: 310006 HANGZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120409 Address after: Hangzhou City, Zhejiang province 310006 Fengqi road Fengqi urban gardens 13-2-1202 Patentee after: Gao Chenyong Address before: Hangzhou City, Zhejiang province 310009 City District primary and generous Donghe homes 1-2-503 Patentee before: Hu Xun |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061025 Termination date: 20130611 |